Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Vinblastine
Vinca Alkaloid · Antineoplastic
Also known as Vinblastine sulfate
Vinca AlkaloidAntineoplastic
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Avoid (carcinogenic and teratogenic in animal studies)
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- AldesleukinSevereDatabaseDDInter
- AmprenavirSevereDatabaseDDInter
- AtazanavirSevereDatabaseDDInter
Mechanism
Vinblastine is a vinca alkaloid that binds to β-tubulin at a distinct site (the vinca domain), inhibiting tubulin polymerization into microtubules and causing dissolution of the mitotic spindle, arresting cells in metaphase. Its dose-limiting toxicity is myelosuppression (particularly leukopenia), in contrast to vincristine where neurotoxicity predominates — a difference attributed to differential accumulation in bone marrow versus neuronal tissue. Vinblastine is a key component of ABVD chemotherapy for Hodgkin lymphoma.
Indications
LeukaemiasLymphomasSolid tumours (e.g. breast cancer, lung cancer)Hodgkin’s disease (as part of ABVD regimen)Hodgkin lymphoma (component of ABVD regimen)Testicular cancer (with bleomycin and cisplatin)Kaposi sarcomaNeuroblastomaLangerhans cell histiocytosisBladder cancerCarcinoma of the breastChoriocarcinomaHodgkin’s diseaseNon-Hodgkin’s lymphomaBreast carcinomaTesticular carcinoma
Dosing
- Adult
- Consult product literature.
- Renal adjustment
- Avoid in severe impairment. Dose reduction may be required in combined renal and hepatic impairment.
- Hepatic adjustment
- Avoid in severe impairment. Dose reduction may be required in combined renal and hepatic impairment.
Pharmacokinetics
Half-life
23 h
Metabolism
Extensively by hepatic CYPs.
Excretion
Metabolites are excreted in the bile. Only a small fraction of a dose (<15%) is found unchanged in the urine.
Contraindications
- Pregnancy (carcinogenic and teratogenic in animal studies)
- Severe hepatic impairment
- Severe renal impairment
Side effects
Common
AnaemiaAppetite decreasedLeucopeniaNauseaThrombocytopeniaVomitingAlopeciaInfectionInfluenza-like illnessPhotosensitivity reactionSkin reactionsLeukopenia (maximal within 7 to 10 days, recovery within 7 days)Mild neurological manifestations (least neurotoxic vinca alkaloid)AnorexiaDiarrheaLoss of hairStomatitisDermatitisSyndrome of inappropriate secretion of ADH (SIADH)Neurotoxicity (less marked than vincristine)Alopecia (less marked than vincristine)
Serious
- Agranulocytosis
- Confusion
- Diarrhoea
- Flushing
- Headache
- Hepatic disorders
- Lethargy
- Pancytopenia
- Paraesthesia
- Renal impairment
- Seizure
- Visual impairment
- Syndrome of inappropriate secretion of antidiuretic hormone (SIADH)
- Cellulitis and phlebitis (from extravasation during injection)
- Bone marrow depression
- Local tissue necrosis if extravasation occurs
Pregnancy & lactation
Pregnancy
Avoid (carcinogenic and teratogenic in animal studies)
Lactation
Discontinue breast-feeding.
Drug interactions
Aldesleukin
Severe
Database
Drug interaction classified as: others
Source: DDInter
Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Boceprevir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Ceritinib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clarithromycin
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cobicistat
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Related guidelines
Other Vinca Alkaloid drugs
Ask House about Vinblastine
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, Katzung·Verified: 2026-05-10 · House clinical team